500 related articles for article (PubMed ID: 15042374)
1. Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.
Kindzelskii AL; Amhad I; Keller D; Zhou MJ; Haugland RP; Garni-Wagner BA; Gyetko MR; Todd RF; Petty HR
Histochem Cell Biol; 2004 Apr; 121(4):299-310. PubMed ID: 15042374
[TBL] [Abstract][Full Text] [Related]
2. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
3. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
4. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
5. Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells.
Wickström SA; Veikkola T; Rehn M; Pihlajaniemi T; Alitalo K; Keski-Oja J
Cancer Res; 2001 Sep; 61(17):6511-6. PubMed ID: 11522648
[TBL] [Abstract][Full Text] [Related]
6. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
7. Regulation of urokinase receptor proteolytic function by the tetraspanin CD82.
Bass R; Werner F; Odintsova E; Sugiura T; Berditchevski F; Ellis V
J Biol Chem; 2005 Apr; 280(15):14811-8. PubMed ID: 15677461
[TBL] [Abstract][Full Text] [Related]
8. Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies.
Floridon C; Nielsen O; Holund B; Sunde L; Westergaard JG; Thomsen SG; Teisner B
Placenta; 1999 Nov; 20(8):711-21. PubMed ID: 10527826
[TBL] [Abstract][Full Text] [Related]
9. Urokinase induces receptor mediated brain tumor cell migration and invasion.
MacDonald TJ; DeClerck YA; Laug WE
J Neurooncol; 1998 Dec; 40(3):215-26. PubMed ID: 10066093
[TBL] [Abstract][Full Text] [Related]
10. The urokinase receptor is required for human monocyte chemotaxis in vitro.
Gyetko MR; Todd RF; Wilkinson CC; Sitrin RG
J Clin Invest; 1994 Apr; 93(4):1380-7. PubMed ID: 8163642
[TBL] [Abstract][Full Text] [Related]
11. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
12. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.
Zhou HM; Nichols A; Meda P; Vassalli JD
EMBO J; 2000 Sep; 19(17):4817-26. PubMed ID: 10970872
[TBL] [Abstract][Full Text] [Related]
13. Localization of urokinase type plasminogen activator to focal adhesions requires ligation of vitronectin integrin receptors.
Wilcox-Adelman SA; Wilkins-Port CE; McKeown-Longo PJ
Cell Adhes Commun; 2000; 7(6):477-90. PubMed ID: 11051458
[TBL] [Abstract][Full Text] [Related]
14. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
15. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
16. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae.
Stahl A; Mueller BM
J Cell Biol; 1995 Apr; 129(2):335-44. PubMed ID: 7721938
[TBL] [Abstract][Full Text] [Related]
17. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
[TBL] [Abstract][Full Text] [Related]
18. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
19. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
Lund IK; Illemann M; Thurison T; Christensen IJ; Høyer-Hansen G
Curr Drug Targets; 2011 Nov; 12(12):1744-60. PubMed ID: 21707477
[TBL] [Abstract][Full Text] [Related]
20. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]